Activation_NN of_IN Mitogen-Activated_NP Protein_NP Kinase_NP and_CC NF-kappaB_NP Pathways_NP by_IN a_DT Kaposi_NP 's_POS Sarcoma-Associated_NP Herpesvirus_NP K15_NP Membrane_NP Protein_NP The_DT K15_NP gene_NN of_IN Kaposi_NP 's_POS sarcoma-associated_JJ herpesvirus_NN (_( also_RB known_VBN as_IN human_JJ herpesvirus_NP 8_CD )_) consists_VBZ of_IN eight_CD alternatively_RB spliced_VBN exons_NNS and_CC has_VBZ been_VBN predicted_VBN to_TO encode_VB membrane_NN proteins_NNS with_IN a_DT variable_JJ number_NN of_IN transmembrane_NN regions_NNS and_CC a_DT common_JJ C-terminal_JJ cytoplasmic_JJ domain_NN with_IN putative_JJ binding_JJ sites_NNS for_IN SH2_NP and_CC SH3_NP domains_NNS ,_, as_RB well_RB as_IN for_IN tumor_NN necrosis_NN factor_NN receptor-associated_JJ factors_NNS ._SENT These_DT features_NNS are_VBP reminiscent_JJ of_IN the_DT latent_JJ membrane_NN proteins_NNS LMP-1_NP and_CC LMP2A_NP of_IN Epstein-Barr_NP virus_NN and_CC ,_, more_RBR distantly_RB ,_, of_IN the_DT STP_NP ,_, Tip_NP ,_, and_CC Tio_NP proteins_NNS of_IN the_DT related_JJ gamma2-herpesviruses_NNS herpesvirus_NN saimiri_NN and_CC herpesvirus_NN ateles_NNS ._SENT These_DT viral_JJ membrane_NN proteins_NNS can_MD activate_VB a_DT number_NN of_IN intracellular_JJ signaling_VBG pathways_NNS ._SENT We_PP have_VBP therefore_RB examined_VBN the_DT abilities_NNS of_IN different_JJ K15-encoded_NP proteins_NNS to_TO initiate_VB intracellular_JJ signaling_VBG ._SENT We_PP found_VBD that_IN a_DT 45-kDa_JJ K15_NP protein_NN derived_VBN from_IN all_DT eight_CD K15_NP exons_NNS and_CC containing_VBG 12_CD predicted_VBN transmembrane_NN domains_NNS in_IN addition_NN to_TO the_DT cytoplasmic_JJ domain_NN activated_VBD the_DT Ras/mitogen-activated_JJ protein_NN kinase_NN (_( MAPK_NP )_) and_CC NF-kappaB_NP pathways_NNS ,_, as_RB well_RB as_IN (_( more_JJR weakly_JJ )_) the_DT c-Jun_NP N-terminal_NP kinase/SAPK_NN pathway_NN ._SENT Activation_NN of_IN the_DT MAPK_NP and_CC NF-kappaB_NP pathways_NNS required_VBD phosphorylation_NN of_IN tyrosine_NN residue_NN 481_CD within_IN a_DT putative_JJ SH2-binding_NP site_NN (_( YEEVL_NP )_) ._SENT This_DT motif_NN was_VBD phosphorylated_JJ by_IN the_DT tyrosine_NN kinases_NNS Src_NP ,_, Lck_NP ,_, Yes_NP ,_, Hck_NP ,_, and_CC Fyn_NP ._SENT The_DT region_NN containing_VBG the_DT YEEVL_NP motif_NN interacted_VBN with_IN tumor_NN necrosis_NN factor_NN receptor-associated_JJ factor_NN 2_CD (_( TRAF-2_NP )_) ,_, and_CC a_DT dominant_JJ negative_JJ TRAF-2_NP mutant_NN inhibited_VBD the_DT K15-mediated_NP activation_NN of_IN the_DT Ras/MAPK_NP pathway_NN ,_, suggesting_VBG the_DT involvement_NN of_IN TRAF-2_NP in_IN the_DT initiation_NN of_IN these_DT signaling_VBG routes_NNS ._SENT In_IN contrast_NN ,_, several_JJ smaller_JJR K15_NP protein_NN isoforms_NNS activated_VBD these_DT pathways_NNS only_RB weakly_RB ._SENT All_DT of_IN the_DT K15_NP isoforms_NNS tested_VBD were_VBD ,_, however_RB ,_, localized_VBN in_IN lipid_NN rafts_NNS ,_, suggesting_VBG that_DT incorporation_NN into_IN lipid_NN rafts_NNS is_VBZ not_RB sufficient_JJ to_TO initiate_VB signaling_VBG ._SENT Additional_JJ regions_NNS of_IN K15_NP ,_, located_VBN presumably_RB in_IN exons_NNS 2_CD to_TO 5_CD ,_, may_MD therefore_RB contribute_VB to_TO the_DT activation_NN of_IN these_DT pathways_NNS ._SENT These_DT findings_NNS illustrate_VBP that_IN the_DT 45-kDa_JJ K15_NP protein_NN engages_VBZ pathways_NNS similar_JJ to_TO LMP1_NP ,_, LMP2A_NP ,_, STP_NP ,_, Tip_NP ,_, and_CC Tio_NP but_CC combines_VBZ functional_JJ features_NNS that_WDT are_VBP separated_VBN between_IN LMP1_NP and_CC LMP2A_NP or_CC STP_NP and_CC Tip_NP ._SENT Kaposi_NP 's_POS sarcoma_NN (KS)-associated_JJ herpesvirus_NN (_( KSHV_NP )_) or_CC human_JJ herpesvirus_NN 8_CD is_VBZ a_DT human_JJ type_NN 2_CD gammaherpesvirus_NNS found_VBN in_IN all_DT forms_NNS of_IN KS_NP ,_, in_IN primary_JJ effusion_NN lymphoma_NN (_( PEL_NP )_) ,_, and_CC in_IN the_DT plasma_NN cell_NN variant_NN of_IN multicentric_JJ Castleman_NP 's_POS disease_NN ._SENT Strong_JJ epidemiological_JJ evidence_NN suggests_VBZ that_IN KSHV_NP plays_VBZ an_DT indispensable_JJ role_NN in_IN the_DT pathogenesis_NN of_IN KS_NP but_CC that_IN additional_JJ factors_NNS ,_, such_JJ as_IN immune_JJ suppression_NN or_CC coinfection_NN with_IN HIV_NP ,_, are_VBP required_VBN for_IN the_DT manifestation_NN of_IN this_DT tumor_NN ._SENT KSHV_NP is_VBZ present_JJ in_IN the_DT endothelial_JJ and_CC spindle_VB (_( tumor_NN )_) cells_NNS of_IN KS_NP lesions_NNS ,_, in_IN PEL_NP cells_NNS ,_, and_CC in_IN perifollicular_JJ B_NP cells_NNS of_IN multicentric_JJ Castleman_NP 's_POS disease_NN ,_, where_WRB it_PP persists_VBZ in_IN a_DT latent_JJ form_NN with_IN limited_JJ viral_JJ gene_NN expression_NN ._SENT In_IN these_DT tumor_NN cells_NNS ,_, lytic_JJ viral_JJ replication_NN occurs_VBZ in_IN a_DT subpopulation_NN of_IN KSHV-infected_NP cells_NNS ._SENT The_DT K15_NP gene_NN of_IN KSHV_NP is_VBZ located_VBN adjacent_JJ to_TO the_DT terminal_JJ repeat_NN region_NN at_IN the_DT right_JJ end_NN of_IN the_DT KSHV_NP long_JJ unique_JJ coding_VBG region_NN and_CC consists_VBZ of_IN eight_CD differentially_RB spliced_VBN exons_NNS ._SENT The_DT sequences_NNS of_IN all_DT of_IN the_DT K15_NP cDNA_NN clones_NNS isolated_VBD so_RB far_RB (_( ,_, ;_: M._NP M._NP Brinkmann_NP et_FW al._FW ,_, unpublished_JJ data_NNS )_) are_VBP predicted_VBN to_TO contain_VB a_DT common_JJ C-terminal_JJ cytoplasmic_JJ region_NN linked_VBN to_TO a_DT variable_JJ number_NN of_IN transmembrane_NN domains_NNS ._SENT The_DT cytoplasmic_JJ region_NN (_( amino_NN acids_NNS [_SYM aa_NN ]_SYM 355_CD to_TO 489_CD )_) contains_VBZ one_CD putative_JJ SH2-binding_NP site_NN motif_NN ,_, Y481EEVL_NP ,_, a_DT second_JJ tyrosine-containing_NN motif_NN (_( Y431ASIL_NP )_) of_IN the_DT general_JJ Yxxtheta_NP consensus_NN found_VBD in_IN SH2-binding_NP sites_NNS and_CC cytoplasmic_JJ internalization_NN motifs_NNS ,_, a_DT putative_JJ proline-rich_JJ SH3-binding_NP site_NN ,_, and_CC a_DT putative_JJ TRAF-binding_NP site_NN (_( A473TQPTDD_NN )_) ._SENT These_DT sequence_NN motifs_NNS are_VBP conserved_VBN between_IN the_DT two_CD highly_RB divergent_JJ M_NN and_CC P_NN genotypes_NNS of_IN KSHV_NP that_WDT have_VBP been_VBN found_VBN in_IN this_DT region_NN of_IN the_DT KSHV_NP genome_NN ,_, suggesting_VBG the_DT conservation_NN of_IN associated_VBN functional_JJ properties_NNS ._SENT Phosphorylation_NN of_IN Y481_NP in_IN the_DT YEEVL_NP motif_NN and_CC binding_VBG of_IN TRAF-1_NP ,_, -2_CD ,_, and_CC -3_CD to_TO the_DT cytoplasmic_JJ domain_NN of_IN K15_NP have_VBP been_VBN observed_VBN ._SENT The_DT combination_NN of_IN multiple_JJ transmembrane_NN regions_NNS with_IN a_DT cytoplasmic_JJ domain_NN that_WDT can_MD be_VB phosphorylated_JJ on_IN tyrosines_NNS and/or_CC interact_VB with_IN TRAFs_NP is_VBZ reminiscent_JJ of_IN the_DT latent_JJ membrane_NN proteins_NNS LMP1_NP and_CC LMP2A_NP of_IN Epstein-Barr_NP virus_NN (_( EBV_NP )_) ._SENT LMP1_NP and_CC LMP2A_NP are_VBP both_CC located_VBN at_IN the_DT ends_NNS of_IN the_DT coding_VBG region_NN of_IN the_DT EBV_NP genome_NN ,_, with_IN LMP2A_NP located_VBN in_IN the_DT position_NN corresponding_JJ to_TO that_DT of_IN K15_NP ,_, while_IN LMP1_NP occupies_VBZ the_DT position_NN corresponding_JJ to_TO that_DT of_IN another_DT KSHV_NP membrane_NN protein_NN ,_, K1_NP ._SENT K1_NP has_VBZ transforming_VBG properties_NNS and_CC triggers_VBZ a_DT number_NN of_IN intracellular_JJ signaling_VBG pathways_NNS ._SENT LMP1_NP is_VBZ considered_VBN to_TO be_VB essential_JJ for_IN the_DT tumorigenic_JJ properties_NNS of_IN EBV_NP by_IN virtue_NN of_IN its_PP$ ability_NN to_TO activate_VB the_DT pathways_NNS for_IN NF-kappaB_NP ,_, c-Jun_NP N-terminal_NP kinase_NN (JNK)/SAPK_NN ,_, p38_NP MAPK_NP ,_, and_CC JAK/STAT_NP (_( reviewed_VBN in_IN reference_NN )_) ._SENT Activation_NN of_IN these_DT signaling_VBG pathways_NNS requires_VBZ the_DT multimerization_NN of_IN LMP-1_JJ molecules_NNS in_IN the_DT membrane_NN through_IN its_PP$ six_CD membrane-spanning_NN domains_NNS and_CC the_DT interaction_NN of_IN cellular_JJ signaling_VBG components_NNS with_IN different_JJ regions_NNS in_IN its_PP$ cytoplasmic_JJ domain_NN ._SENT Among_IN these_DT ,_, so-called_JJ C-terminal_JJ activator_NN region_NN 1_CD (_( CTAR-1_NP )_) interacts_VBZ with_IN TRAF-1_NP ,_, -2_CD ,_, -3_CD ,_, and_CC -5_CD and_CC activates_VBZ the_DT NF-kappaB_NP pathway_NN ,_, while_IN the_DT more_RBR distal_JJ region_NN CTAR-2_NN associates_NNS directly_RB with_IN TRADD_NN and_CC indirectly_RB with_IN TRAF-2_NP and_CC initiates_VBZ the_DT cascades_NNS leading_VBG to_TO the_DT activation_NN of_IN JNK/SAPK_NP and_CC NF-kappaB_NP ._SENT The_DT region_NN between_IN CTAR-1_NP and_CC -2_NP has_VBZ been_VBN reported_VBN to_TO be_VB involved_VBN in_IN triggering_VBG of_IN the_DT JAK/STAT_NP cascade_NN ._SENT LMP2A_NP consists_VBZ of_IN an_DT N-terminal_JJ cytoplasmic_JJ domain_NN of_IN 119_CD aa_NN and_CC a_DT membrane_NN anchor_NN region_NN of_IN 12_CD transmembrane_NN segments_NNS ._SENT The_DT cytoplasmic_JJ domain_NN contains_VBZ several_JJ SH2-binding_NP sites_NNS surrounding_VBG tyrosine_NN residues_NNS ,_, of_IN which_WDT two_CD ,_, Y74_NP and_CC Y85_NP ,_, are_VBP grouped_VBN as_IN an_DT ITAM_NP (_( immune_JJ receptor_NN tyrosine-based_JJ activation_NN motif_NN )_) (_( reviewed_VBN in_IN reference_NN )_) ._SENT Tyrosine_NN 112_CD is_VBZ part_NN of_IN a_DT YEEA_NP motif_NN that_WDT resembles_VBZ the_DT YEEI/L_NP consensus_NN sequence_NN for_IN Src_NP SH2-binding_NP domains_NNS ._SENT LMP2A_NP is_VBZ expressed_VBN in_IN latently_RB EBV-infected_JJ circulating_VBG B_NN cells_NNS and_CC in_IN B-lymphoma_NP cells_NNS of_IN large-cell_NN lymphoma_NN in_IN immunocompromised_JJ individuals_NNS or_CC those_DT with_IN Hodgkin_NP 's_POS disease_NN (_( reviewed_VBN in_IN reference_NN )_) ._SENT In_IN B_NP cells_NNS ,_, binding_VBG of_IN the_DT Src_NP kinase_NN Lyn_NP to_TO the_DT YEEA_NP motif_NN leads_VBZ to_TO phosphorylation_NN of_IN the_DT ITAM_NP ,_, which_WDT in_IN turn_NN leads_VBZ to_TO recruitment_NN of_IN the_DT tyrosine_NN kinase_NN Syk_NP ._SENT This_DT sequence_NN of_IN events_NNS is_VBZ similar_JJ to_TO the_DT early_JJ signaling_VBG steps_NNS that_WDT occur_VBP after_IN triggering_VBG of_IN the_DT B-_NP or_CC T-cell_NN receptor_NN :_: here_RB ,_, the_DT initial_JJ phosphorylation_NN of_IN the_DT ITAM_NN in_IN cytoplasmic_JJ components_NNS of_IN the_DT receptor_NN complex_NN leads_VBZ to_TO the_DT recruitment_NN of_IN Syk_NP (_( in_IN B_NP cells_NNS )_) or_CC Zap70_NP (_( in_IN T_NN cells_NNS )_) and_CC binding_VBG of_IN the_DT tandem_JJ SH2_NP domains_NNS in_IN the_DT recruited_VBN kinases_NNS to_TO the_DT two_CD phosphorylated_JJ tyrosine_NN residues_NNS in_IN the_DT ITAM_NP ._SENT The_DT interactions_NNS of_IN LMP2A_NP with_IN the_DT components_NNS of_IN these_DT signaling_VBG cascades_NNS lead_VB to_TO inhibition_NN of_IN B-cell_NN receptor_NN signaling_VBG ._SENT LMP2A_NP interacts_VBZ with_IN the_DT WW_NP domain_NN containing_VBG ubiquitin_NN ligases_NNS Nedd4_NP ,_, WWP2/AIP2_NP ,_, and_CC AIP4_NP via_IN a_DT PPPPY_JJ motif_NN and_CC thereby_RB induces_VBZ the_DT ubiquitination_NN and_CC rapid_JJ proteasome-mediated_JJ turnover_NN of_IN the_DT LMP2A-associated_JJ protein_NN tyrosine_NN kinases_NNS (_( PTKs_NP )_) ._SENT It_PP is_VBZ thought_VBN that_IN this_DT contributes_VBZ to_TO the_DT survival_NN of_IN EBV_NP in_IN infected_JJ B_NP cells_NNS ,_, since_IN the_DT effect_NN of_IN LMP2A_NP would_MD be_VB to_TO inhibit_VB the_DT activation_NN of_IN infected_JJ B_NP cells_NNS by_IN antigen_NN and_CC with_IN it_PP the_DT activation_NN of_IN the_DT viral_JJ lytic_JJ cycle_NN ._SENT However_RB ,_, transgenic_JJ expression_NN of_IN LMP2A_NP in_IN murine_JJ B_NP cells_NNS increases_VBZ B-cell_NN survival_NN and_CC therefore_RB LMP2A_NP may_MD also_RB make_VB a_DT more_RBR direct_JJ contribution_NN to_TO the_DT survival_NN of_IN EBV-infected_NP B_NP cells_NNS ._SENT Unlike_IN its_PP$ counterpart_NN LMP1_NP ,_, however_RB ,_, LMP2A_NP is_VBZ not_RB required_VBN for_IN the_DT immortalization_NN of_IN EBV-infected_NP B_NP cells_NNS ._SENT LMP2A_NP is_VBZ also_RB expressed_VBN in_IN the_DT tumor-derived_JJ epithelial_JJ cells_NNS of_IN nasopharyngeal_JJ carcinoma_NN (_( reviewed_VBN in_IN reference_NN )_) ._SENT Experimental_JJ expression_NN of_IN LMP2A_NP in_IN epithelial_JJ cells_NNS leads_VBZ to_TO the_DT acquisition_NN of_IN phenotypic_JJ characteristics_NNS of_IN transformation_NN such_JJ as_IN growth_NN in_IN soft_JJ agar_NN and_CC dedifferentiation_NN and_CC the_DT activation_NN by_IN LMP2A_NP of_IN the_DT phosphatidylinositol_NN 3_CD kinase/Akt_NN pathway_NN is_VBZ important_JJ for_IN this_DT LMP2A-induced_JJ phenotype_NN ._SENT In_IN epithelial_JJ cells_NNS ,_, LMP2A_NP phosphorylation_NN can_MD be_VB triggered_VBN by_IN adherence_NN of_IN these_DT cells_NNS to_TO extracellular_JJ matrix_NN proteins_NNS and_CC involves_VBZ the_DT regulator_NN of_IN Src_NP ,_, the_DT C-terminal_NP Src_NP kinase_NN Csk_NP ._SENT LMP2A_NP also_RB binds_VBZ to_TO and_CC is_VBZ phosphorylated_JJ by_IN the_DT mitogen-activated_JJ protein_NN kinase_NN (_( MAPK_NP )_) ERK1_NP ._SENT A_DT recent_JJ report_NN found_VBD that_IN LMP2A_NP activates_VBZ the_DT MAPKs_NP Erk_NP and_CC JNK_NP in_IN B_NP cells_NNS ,_, but_CC others_NNS have_VBP not_RB observed_VBN Erk_NP activation_NN by_IN LMP2A_NP in_IN epithelial_JJ cells_NNS ._SENT Similar_JJ to_TO the_DT EBV_NP LMPs_NP ,_, at_IN least_JJS two_CD New_NP World_NP primate_NN gamma2-herpesviruses_NNS ,_, herpesvirus_NP saimiri_NP (_( HVS_NP )_) and_CC herpesvirus_NN ateles_NNS (_( HVA_NP )_) ,_, also_RB encode_VB membrane-associated_JJ proteins_NNS ,_, STP_NP ,_, Tip_NP (_( HVS_NP )_) ,_, and_CC Tio_NP (_( HVA_NP )_) ,_, that_WDT can_MD either_RB bind_VB to_TO TRAFs_NP (_( STP_NP )_) or_CC are_VBP phosphorylated_JJ by_IN members_NNS of_IN the_DT Src_NP kinase_NN family_NN (_( Tip_NP ,_, Tio_NP )_) (_( ;_: reviewed_VBN in_IN reference_NN )_) ._SENT STP_NP of_IN HVS_NP strains_NNS A_NP and_CC C_NP is_VBZ required_VBN for_IN the_DT transforming_VBG and/or_CC lymphomagenic_JJ potential_NN of_IN these_DT viruses_NNS (_( reviewed_VBN in_IN reference_NN )_) ._SENT HVS_NP and_CC HVA_NP are_VBP T_NN lymphotropic_JJ ,_, and_CC HVS_NP strain_NN C_NP Tip_NP is_VBZ phosphorylated_JJ by_IN the_DT Src_NP kinase_NN Lck_NP and_CC can_MD inhibit_VB T-cell_NN receptor-induced_NNS signaling_VBG ._SENT Tip_NP may_MD also_RB have_VB a_DT modulatory_JJ role_NN in_IN STP-mediated_JJ transformation_NN ._SENT Given_VBN the_DT presumed_JJ roles_NNS of_IN LMP1_NP ,_, LMP2A_NP ,_, STP_NP ,_, Tip_NP ,_, and_CC Tio_NP in_IN immortalization_NN ,_, dedifferentiation_NN ,_, maintenance_NN of_IN latency_NN ,_, and_CC regulation_NN of_IN the_DT viral_JJ lytic_JJ replication_NN cycle_NN ,_, we_PP wanted_VBD to_TO investigate_VB whether_IN KSHV_NP K15-derived_NP proteins_NNS have_VBP similar_JJ functions_NNS ._SENT As_IN a_DT first_JJ step_NN ,_, we_PP sought_VBD to_TO identify_VB cellular_JJ signaling_VBG pathways_NNS triggered_VBN by_IN K15_NP proteins_NNS and_CC show_VBP here_RB that_IN the_DT longest_JJS K15_NP isoform_NN ,_, but_CC not_RB the_DT smaller_JJR isoforms_NNS ,_, activate_VBP the_DT Ras/MAPK_NP and_CC NF-kappaB_NP pathways_NNS following_VBG phosphorylation_NN of_IN a_DT tyrosine_NN residue_NN in_IN a_DT YEEVL_NP motif_NN by_IN several_JJ members_NNS of_IN the_DT Src_NP kinase_NN family_NN ._SENT Cell_NN culture_NN methods_NNS ,_, transfections_NNS ,_, and_CC MEK1/2_JJ inhibitors_NNS ._SENT |_SYM The_DT cell_NN lines_NNS HEK_NP (_( human_JJ embryonic_JJ kidney_NN )_) 293-T_NP ,_, HEK_NP 293_CD ,_, and_CC Cos7_NP were_VBD cultured_VBN in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN (_( Gibco_NP )_) supplemented_VBD with_IN 10_CD %_NN heat-inactivated_JJ fetal_JJ calf_NN serum_NN (_( FCS_NN )_) ,_, 50_CD IU_NP of_IN penicillin_NN per_IN ml_NN ,_, 50_CD mug_NN of_IN streptomycin_NN per_IN ml_NN ,_, and_CC 300_CD mug_NN of_IN l-glutamine_NN per_IN ml_NN at_IN 37C_JJ in_IN humidified_VBN air_NN with_IN 5_CD %_NN CO2_NN ._SENT For_IN transfections_NNS ,_, cells_NNS were_VBD grown_VBN to_TO subconfluence_NN in_IN six-well_NN plates_NNS (_( Greiner_NP )_) ._SENT HEK_NP 293-T_NP and_CC 293_CD cells_NNS were_VBD transfected_VBN with_IN FuGENE_NP transfection_NN reagent_NN (_( Roche_NP ;_: FuGENE-to-DNA_NP ratio_NN of_IN 3_CD mul_NN to_TO 1_CD mug_NN )_) ,_, Cos7_JJ cells_NNS were_VBD transfected_VBN with_IN the_DT Effectene_NP transfection_NN reagent_NN (_( Qiagen_NP )_) in_IN accordance_NN with_IN the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Total_JJ amounts_NNS of_IN transfected_JJ DNA_NN were_VBD adjusted_VBN with_IN salmon_NN testis_NN DNA_NP (_( Sigma_NP )_) ._SENT The_DT specific_JJ MEK1/2_NP inhibitors_NNS PD98059_NP and_CC UO126_NP (_( Calbiochem_NP )_) were_VBD used_VBN at_IN a_DT concentration_NN of_IN 50_CD muM_NN from_IN a_DT 50_CD mM_NP stock_NN solution_NN in_IN dimethyl_NN sulfoxide_NN (_( DMSO_NP )_) ._SENT The_DT inhibitors_NNS were_VBD added_VBN to_TO the_DT medium_JJ 14_CD h_NN after_IN transfection_NN ,_, and_CC cells_NNS were_VBD incubated_VBN for_IN a_DT further_JJR 8_CD h_NN before_IN being_VBG extracted_VBN as_IN described_VBN below_IN ._SENT DNA_NP constructs_VBZ ._SENT |_SYM The_DT full-length_JJ K15_NP cDNA_NN clone_NN (_( K15_NP aa_NN 1_CD to_TO 489_CD )_) from_IN the_DT BCP-1_NP KSHV_NP isolate_NN (_( primary_JJ effusion_NN cell_NN line_NN infected_VBN with_IN KSHV_NP ;_: )_) was_VBD generated_VBN by_IN reverse_JJ transcription_NN (RT)-PCR_NN amplification_NN of_IN the_DT K15_NP region_NN with_IN the_DT forward_RB primer_JJR LRH6for_NP ,_, which_WDT binds_VBZ 192_CD bp_NN upstream_RB of_IN the_DT putative_JJ start_NN codon_NN of_IN K15_NP (_( 5'-ATCCGGAATATTTATGAGCC-3_NP '_POS )_) ,_, and_CC primer_JJR ex8arev_NN ,_, which_WDT binds_VBZ to_TO the_DT start_NN region_NN of_IN open_JJ reading_NN frame_NN 75_CD (_( ORF75_NN )_) 245_CD nucleotides_NNS downstream_JJ of_IN the_DT K15_NP stop_NN codon_NN (_( 5'-CTCCAACCACAGCCCAGTGACG-3_NP '_POS )_) ._SENT The_DT resulting_JJ PCR_NP product_NN was_VBD cloned_VBN into_IN pGEM-T_NP (_( Promega_NP )_) and_CC sequenced_JJ ._SENT The_DT PCR_NP product_NN was_VBD then_RB cloned_VBN into_IN the_DT eucaryotic_JJ expression_NN vector_NN pFJEA_NN by_IN digestion_NN with_IN EcoRI_NP (_( clone_NN MBK15_NP )_) ._SENT Clone_NN 35_CD ,_, which_WDT contains_VBZ a_DT full-length_JJ cDNA_NN (_( exons_NNS 1_CD to_TO 8_CD )_) of_IN K15_NP from_IN the_DT BCBL-1_NP PEL_NP cell_NN line_NN cloned_VBN into_IN the_DT EcoRI/XbaI_NP sites_NNS of_IN pFJEA_NN was_VBD kindly_RB provided_VBN by_IN J.-K_NP ._SENT Choi_NP ._SENT Clone_NN 35_CD contains_VBZ an_DT artificial_JJ Kozak_NP sequence_NN ,_, begins_VBZ at_IN the_DT putative_JJ start_NN codon_NN of_IN K15_NP in_IN exon_NN 1_CD ,_, and_CC contains_VBZ a_DT Flag_NP tag_NN at_IN its_PP$ C-terminal_JJ end_NN ._SENT Plasmid_NP K15_NP ex1-8_NP (_( aa_NN Delta473_NP to_TO 489_CD )_) lacking_VBG the_DT C-terminal_JJ 17_CD aa_NN and_CC plasmid_NP K15_NP ex1-8_NP Y481F_NP carrying_VBG the_DT Y481->F_NP point_NN mutation_NN in_IN the_DT Y481EEVL_NP motif_NN were_VBD generated_VBN by_IN PCR_NP amplification_NN of_IN clone_NN 35_CD with_IN the_DT upstream_JJ primer_NN LAMPB5_NP '_'' (_( 5'-ACAGGATCCTAAAATGAAGACACTCATATTCTTCTGG-3_NP '_POS )_) and_CC the_DT reverse_JJ primer_NN ex8ad1_NN (_( 5'-ACGCCCGGGTTAGGCTTGGGCGGTGTCTATACGGAAGGC-3_NP '_POS )_) or_CC ex8aY:F_NP (_( 5'-TATGAATTCCTAGTTCCTGGGAAATAAAACCTCCTCAAACAGGTC-3_NP '_POS )_) ,_, respectively_RB ._SENT PCR_NP products_NNS were_VBD cloned_VBN into_IN pGEM-T_NN and_CC subsequently_RB cloned_VBN into_IN the_DT NotI_NP site_NN of_IN pFJEA_NN and_CC sequenced_JJ ._SENT The_DT cDNAs_NNS of_IN the_DT K15_NP splice_NN variants_NNS K15_NP ex1/6-8_NP ,_, K15_NP ex1_JJ as/6-8_NN ,_, and_CC K15_NP ex1_JJ as/4-8_NN were_VBD generated_VBN by_IN RT-PCR_NP amplification_NN of_IN the_DT K15_NP region_NN (_( BCP-1_NP KSHV_NP isolate_NN )_) with_IN primers_NNS LR65_NP (_( 5'-ACGATCTAGATCCGGAATATTTATGAGC-3_NP '_POS )_) and_CC ex8arev_NP ,_, followed_VBN by_IN a_DT nested_VBN PCR_NP with_IN forward_RB primer_JJR FJLampfor_NP (_( 5'-ATCGAATTCCATTTACAACAACTCTATTG-3_NP '_POS )_) ,_, binding_VBG 45_CD nucleotides_NNS upstream_RB of_IN the_DT K15_NP start_NN codon_NN ,_, and_CC reverse_JJ primer_NN FJLamprev_NP (_( 5'-ATCGGTACCTAGTTCCTGGGAAATAAAAC-3_NP '_POS )_) ,_, binding_VBG at_IN the_DT K15_NP stop_NN codon_NN ._SENT PCR_NP products_NNS were_VBD cloned_VBN into_IN pGEM-T_NN ,_, sequenced_JJ ,_, and_CC subsequently_RB cloned_VBN into_IN the_DT EcoRI_NP and_CC KpnI_NP sites_NNS of_IN pFJEA_NN ._SENT A_DT plasmid_NN containing_VBG the_DT entire_NN predicted_VBD cytoplasmic_JJ domain_NN (_( aa_NN 355_CD to_TO 489_CD )_) of_IN K15_NP fused_VBD to_TO glutathione_NN S-transferase_NP (_( GST_NP )_) (_( pGEX8A_NP ,_, GST-K15355-489_NP )_) has_VBZ been_VBN previously_RB described_VBN ._SENT A_DT further_RBR GST_JJ fusion_NN plasmid_NN in_IN which_WDT the_DT carboxy-terminal_JJ 17_CD aa_NN of_IN K15_NP were_VBD deleted_VBN (_( GST-K15355-472_NP )_) was_VBD generated_VBN by_IN PCR_NP with_IN the_DT 5_CD '_POS primer_NN GSTex8afor_NP (_( 5'-CAGGGATCCTAAATAGTTACCGACAGAGAAGGGG-3_NP '_POS )_) and_CC the_DT 3_CD '_POS primer_NN ex8arevd1_NN ._SENT Further_JJR deletion_NN constructs_NNS of_IN the_DT K15_NP C-terminal_NP region_NN of_IN the_DT GST-K15_NP fusion_NN protein_NN were_VBD generated_VBN with_IN plasmid_NP pGEX8A_NP (_( GST-K15355-489_NP )_) as_IN the_DT template_NN together_RB with_IN primer_NN GSTex8afor_NP and_CC either_DT reverse_JJ primer_NN ex8arevd2_NN (_( 5'-ACTCCCGGGACCGGACACTAAAATACTGGC-3_NP '_POS )_) to_TO generate_VB GST-K15355-438_NP or_CC reverse_VB primer_JJR ex8arevd4_NN (_( 5'-ACTCCCGGGTGTGGTGTAAGTTCTGGTCCC-3_NP '_POS )_) to_TO generate_VB GST-K15355-373_NP ._SENT PCR_NP products_NNS were_VBD cloned_VBN into_IN pGEX-3X_NP (_( Amersham_NP Pharmacia_NP )_) and_CC sequenced_JJ ._SENT The_DT LMP1-K15355-489_NP chimera_NN ,_, consisting_VBG of_IN the_DT six_CD amino-terminal_JJ transmembrane_NN domains_NNS of_IN LMP1_NP and_CC the_DT cytoplasmic_JJ region_NN of_IN K15_NP ,_, was_VBD constructed_VBN by_IN amplification_NN of_IN the_DT transmembrane_JJ domain_NN of_IN LMP1_NP from_IN plasmid_NP pSG5-LMP1_NN with_IN primers_NNS LMPLAMPa5_NP '_POS (_( 5'-GACGGTACCATGGACTACAAGGACGATGACGACAAGGAACAC_NP GACCTTGAGAGGGGCCCACCG-3_NP '_'' )_) and_CC LMPLAMPa3_NP '_'' (_( 5'-CCTTCTCTGTCGGTAACTATTTACTTCATCACTGTGTCGTTGTCCATGG-3_NP '_POS )_) ._SENT Primer_NP LMPLAMPa5_NP '_POS introduces_VBZ the_DT Flag_NP epitope_NN tag_NN DYKDDDDK_NP (_( sequence_NN underlined_VBN )_) ,_, while_IN the_DT first_JJ 25_CD nucleotides_NNS of_IN LMPLAMPa3_NP '_POS are_VBP homologous_JJ to_TO a_DT region_NN within_IN the_DT carboxy_JJ terminus_NN of_IN K15_NP (_( sequence_NN underlined_VBN )_) ._SENT The_DT resulting_VBG amplicon_NN was_VBD purified_VBN and_CC used_VBN as_IN a_DT primer_NN together_RB with_IN primer_NN LAMPa3_NP '_'' (_( 5'-TATGAATTCCTAGTTCCTGGGAAATAAAAC-3_NP '_POS )_) in_IN a_DT PCR_NP with_IN genomic_JJ BCP-1_JJ DNA_NN as_IN the_DT template_NN ._SENT The_DT resulting_VBG product_NN was_VBD cloned_VBN into_IN pcDNA3.1_JJ (_( Invitrogen_NP )_) and_CC sequenced_JJ ._SENT cDNA_NN plasmids_NNS expressing_VBG Flag-tagged_NP TRAF-1_NP ,_, -2_CD ,_, and_CC -3_CD were_VBD kindly_RB provided_VBN by_IN M._NP Rothe_NP ._SENT Myc-tagged_NP PTK_NP expression_NN plasmids_NNS for_IN Src_NP ,_, Fyn_NP ,_, Hck_NP ,_, Lck_NP ,_, and_CC Yes_NP were_VBD kindly_RB provided_VBN by_IN S._NP Muller_NP ,_, Erlangen_NP ,_, Germany_NP ._SENT pSRalpha-HA-JNK1_JJ and_CC pSRalpha-HA-Erk2_JJ ;_: pCMV-HA-p38_NN ;_: the_DT AP-1_JJ reporter_NN constructs_NNS pRTU14_NN (_( luciferase_NN reporter_NN gene_NN under_IN the_DT control_NN of_IN a_DT minimal_JJ promoter_NN and_CC four_CD TREs_NNS [_SYM TPA_NP response_NN elements_NNS ]_SYM )_) and_CC pRTU1_JJ (_( lacking_VBG the_DT TREs_NP )_) ;_: GST-c-Jun_NP ;_: dominant_JJ negative_JJ mutant_JJ forms_NNS of_IN TRAF-2_NP (_( pRK-TRAF-2_NN [_SYM aa_NN 87_CD to_TO 501_CD ]_SYM )_) ,_, TRAF-6_NP (_( aa_NN 300_CD to_TO 524_CD )_) ,_, and_CC Ras_NP (_( N-17_NP )_) ;_: expression_NN vectors_NNS pCis2_JJ and_CC pRKH5_JJ ;_: and_CC the_DT construct_NN pSV-LMP1_NN have_VBP been_VBN described_VBN previously_RB ._SENT Dominant_JJ negative_JJ Erk2_NP C3_NP (_( Y185->F_NP )_) ,_, RSV_NP Raf_NP C4B_NP ,_, and_CC eucaryotic_JJ expression_NN vector_NN KRSPA_NP (_( Rous_NP sarcoma_NN virus_NN promoter_NN )_) were_VBD kind_NN gifts_NNS from_IN S._NP Ludwig_NP ._SENT The_DT NF-kappaB_NP reporter_NN plasmid_NN p3EnhkappaBconA-Luc_NN containing_VBG three_CD NF-kappaB_NP sites_NNS upstream_RB of_IN the_DT firefly_NN luciferase_NN gene_NN and_CC pSG5-LMP1_NN were_VBD provided_VBN by_IN A._NP Eliopoulos_NP ._SENT Expression_NN and_CC purification_NN of_IN recombinant_JJ proteins_NNS and_CC GST_JJ fusion_NN protein_NN binding_VBG assays_NNS ._SENT |_SYM GST-c-Jun_NP ,_, GST-K15355-489_NP ,_, and_CC GST-K15355-472_NP for_IN radioactive_JJ immunocomplex_JJ kinase_NN assays_NNS were_VBD purified_VBN as_IN described_VBN in_IN reference_NN ._SENT The_DT purified_VBN GST_JJ fusion_NN proteins_NNS eluted_VBN with_IN glutathione_NN were_VBD analyzed_VBN by_IN sodium_NN dodecyl_NN sulfate_NN (SDS)-polyacrylamide_NN gel_NN electrophoresis_NN (_( PAGE_NP )_) ._SENT For_IN GST_JJ pulldown_NN experiments_NNS ,_, Escherichia_NP coli_NNS M15_NP cultures_NNS transformed_VBN with_IN the_DT GST-K15_NP expression_NN plasmids_NNS or_CC GST_NP alone_RB were_VBD grown_VBN at_IN 37C_JJ in_IN 2YT_JJ medium_NN plus_CC ampicillin_NN ,_, induced_VBN at_IN an_DT optical_JJ density_NN at_IN 600_CD nm_NN of_IN 0.2_CD to_TO 0.3_CD with_IN 1_CD mM_NP isopropyl-beta-d-thiogalactopyranoside_NP (_( IPTG_NP )_) ,_, and_CC harvested_VBN by_IN centrifugation_NN 6_CD h_NN after_IN induction_NN ._SENT The_DT pellet_NN was_VBD resuspended_VBN in_IN 1,000_CD mul_NN of_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) plus_CC protease_NN inhibitors_NNS per_IN 10_CD ml_NN of_IN culture_NN to_TO an_DT optical_JJ density_NN at_IN 600_CD nm_NN of_IN 2.5_CD ._SENT After_IN sonication_NN on_IN ice_NN ,_, Triton_NP X-100_NP was_VBD added_VBN to_TO a_DT 1_CD %_NN final_JJ concentration_NN ,_, and_CC the_DT cells_NNS were_VBD kept_VBN on_IN ice_NN for_IN 10_CD min_NN and_CC then_RB centrifuged_VBN for_IN 15_CD min_NN at_IN 14,000_CD x_NN g_NN at_IN 4C_JJ ._SENT The_DT supernatant_JJ was_VBD adsorbed_VBN onto_IN 20_CD to_TO 50_CD mul_NN of_IN glutathione_NN Sepharose_NN beads_NNS for_IN 1_CD h_NN at_IN 4C_JJ ,_, after_IN which_WDT the_DT beads_NNS were_VBD washed_VBN twice_RB in_IN PBS_NP and_CC then_RB once_RB in_IN 1_CD %_NN NP-40_JJ lysis_NN buffer_NN (_( 50_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.4_CD ]_SYM ,_, 150_CD mM_NP NaCl_NP ,_, 1_CD mM_NP EDTA_NP ,_, 1_CD %_NN NP-40_NN )_) ._SENT HEK_NP 293_CD or_CC 293-T_JJ cells_NNS were_VBD transfected_VBN as_IN mentioned_VBN in_IN the_DT section_NN on_IN coimmunoprecipitation_NN but_CC with_IN 1_CD mug_NN of_IN cDNA_NN expression_NN constructs_NNS per_IN well_RB of_IN a_DT six-well_NN plate_NN of_IN either_DT Flag-tagged_NP TRAF-1_NP ,_, -2_CD ,_, or_CC -3_CD (_( HEK_NP 293_CD )_) or_CC the_DT myc-tagged_JJ Src_NP kinase_NN Src_NP ,_, Lck_NP ,_, Yes_NP ,_, Fyn_NP ,_, or_CC Hck_NP (_( HEK_NP 293-T_NP )_) ._SENT At_IN 48_CD h_NN after_IN transfection_NN ,_, cells_NNS were_VBD washed_VBN once_RB on_IN ice_NN with_IN PBS_NP and_CC lysed_VBN in_IN 1_CD %_NN NP-40_JJ lysis_NN buffer_NN containing_VBG protease_NN inhibitors_NNS for_IN 10_CD min_NN on_IN ice_NN ._SENT Cell_NN lysates_NNS were_VBD centrifuged_VBN at_IN 14,000_CD x_NN g_NN for_IN 10_CD min_NN at_IN 4C_JJ and_CC precleared_JJ by_IN incubation_NN with_IN 50_CD mul_NN of_IN glutathione_NN beads_NNS for_IN 1_CD h_NN at_IN 4C_JJ ._SENT Cleared_VBN lysates_NNS were_VBD then_RB incubated_VBN for_IN 1_CD h_NN or_CC overnight_JJ at_IN 4C_JJ with_IN either_DT GST_JJ control_NN protein_NN or_CC GST-K15_NP fusion_NN protein_NN immobilized_VBN to_TO glutathione_NN beads_NNS ._SENT The_DT beads_NNS were_VBD washed_VBN three_CD times_NNS in_IN 1_CD %_NN NP-40_JJ lysis_NN buffer_NN ,_, and_CC proteins_NNS adsorbed_VBN to_TO beads_NNS were_VBD boiled_VBN in_IN 50_CD mul_NN of_IN SDS_NP electrophoresis_NN sample_NN buffer_NN and_CC analyzed_VBD by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG ._SENT Generation_NN of_IN rabbit_NN polyclonal_NN and_CC mouse_NN monoclonal_NN antibodies_NNS to_TO the_DT C-terminal_NP K15_NP domain_NN ._SENT |_SYM The_DT carboxy-terminal_JJ region_NN of_IN K15_NP was_VBD transferred_VBN from_IN plasmid_NP pGEX8A_NP to_TO plasmid_NP pGEX6A_NP ._SENT The_DT GST-K15355-489_NP fusion_NN protein_NN was_VBD prepared_VBN from_IN 1-liter_NP E._NP coli_NNS (_( M15_NP )_) cultures_NNS ,_, and_CC the_DT K15_NP portion_NN of_IN the_DT protein_NN was_VBD cleaved_VBN by_IN incubation_NN in_IN the_DT presence_NN of_IN PreScission_NN protease_NN while_IN still_RB bound_VBN to_TO GST_JJ beads_NNS in_IN accordance_NN with_IN the_DT manufacturer_NN 's_POS (_( Amersham_NP Pharmacia_NP )_) instructions_NNS ._SENT The_DT cleaved_VBN C-terminal_JJ cytoplasmic_JJ domain_NN of_IN K15_NP (_( aa_NN 355_CD to_TO 489_CD )_) was_VBD eluted_VBN with_IN PBS_NP and_CC used_VBN to_TO immunize_VB two_CD rabbits_NNS in_IN accordance_NN with_IN standard_JJ protocols_NNS ._SENT Noncleaved_JJ GST-K15355-489_NP fusion_NN protein_NN was_VBD used_VBN to_TO immunize_VB mice_NNS in_IN accordance_NN with_IN standard_JJ protocols_NNS ._SENT Immunocomplex_JJ kinase_NN assays_NNS and_CC Western_JJ blotting_VBG (_( immunoblotting_NN )_) ._SENT |_SYM As_RB indicated_VBN in_IN the_DT figure_NN legends_NNS ,_, HEK_NP 293-T_JJ cells_NNS were_VBD cotransfected_VBN with_IN 1_CD mug_NN of_IN hemagglutinin_NN (HA)-tagged_VBN MAPK_NP and_CC 1_CD mug_NN of_IN K15_NP cDNA_NN expression_NN constructs_NNS with_IN FuGENE_NP ._SENT Where_WRB indicated_VBN ,_, 700_CD ng_NNS of_IN dominant_JJ negative_JJ mutants_NNS or_CC their_PP$ respective_JJ empty_JJ expression_NN vectors_NNS were_VBD also_RB cotransfected_JJ ._SENT After_IN transfection_NN ,_, cells_NNS were_VBD maintained_VBN in_IN medium_NN containing_VBG 1_CD %_NN FCS_NN to_TO downregulate_VB serum-activated_JJ signaling_VBG pathways_NNS ._SENT At_IN 24_CD h_NN after_IN transfection_NN ,_, cells_NNS were_VBD lysed_VBN in_IN TBS-T_NP buffer_NN (_( 20_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.4_CD ]_SYM ,_, 150_CD mM_NP NaCl_NP ,_, 1_CD mM_NP EDTA_NP ,_, 1_CD %_NN Triton_NP X-100_NP ;_: the_DT protease_NN inhibitors_NNS phenylmethylsulfonyl_JJ fluoride_NN [_SYM PMSF_NP ;_: 1_CD mM_NN ]_SYM ,_, leupeptin_NN [_SYM 50_CD muM_NN ]_SYM ,_, aprotinin_NN [_SYM 100_CD U/ml_NN ]_SYM ,_, benzamidine_NN [_SYM 200_CD muM_NN ]_SYM ,_, and_CC pepstatin_NP A_NP [_SYM 1_CD muM_NN ]_SYM ;_: and_CC the_DT phosphatase_NN inhibitors_NNS sodium_NN orthovanadate_NN ,_, beta-glycerophosphate_NN ,_, sodium_NN molybdate_NN ,_, sodium_NN fluoride_NN ,_, sodium_NN pyrophosphate_NN at_IN 0.5_CD mM_NNS )_) ._SENT Cleared_VBN lysates_NNS were_VBD incubated_VBN overnight_RB with_IN anti-HA_NP monoclonal_NN antibody_NN 12CA5_NP (_( Boehringer_NP Mannheim_NP )_) immobilized_VBD to_TO protein_NN G_NP Sepharose_NP beads_NNS (_( Amersham_NP Pharmacia_NP )_) to_TO immunoprecipitate_VB HA-tagged_JJ kinases_NNS ._SENT Afterwards_RB ,_, samples_NNS were_VBD centrifuged_VBN and_CC the_DT supernatants_NNS were_VBD analyzed_VBN for_IN expression_NN of_IN K15_NP constructs_NNS by_IN Western_NP blotting_VBG ._SENT Beads_NNS with_IN bound_JJ MAPK_NP were_VBD washed_VBN twice_RB with_IN TBS-T_NP and_CC twice_RB with_IN kinase_NN reaction_NN buffer_NN (_( 20_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.4_CD ]_SYM ,_, 20_CD mM_NP NaCl_NP ,_, 1_CD mM_NP dithiothreitol_NN ,_, 10_CD mM_NP MgCl2_NP ,_, 2_CD muM_NN ATP_NP ,_, 0.5_CD mM_NP beta-glycerophosphate_NN ,_, 0.5_CD mM_NP sodium_NN orthovanadate_NN )_) ._SENT In_IN vitro_NN kinase_NN reactions_NNS to_TO assay_VB the_DT activity_NN of_IN immunoprecipitated_JJ HA-MAPK_NP were_VBD performed_VBN in_IN kinase_NN reaction_NN buffer_NN in_IN the_DT presence_NN of_IN 10_CD muCi_NNS of_IN [_SYM gamma-32P]ATP_NN (_( 10_CD mCi/ml_NN ;_: Hartmann_NP Analytics_NP )_) per_IN reaction_NN sample_NN with_IN 200_CD ng_NNS of_IN bovine_JJ myelin_NN basic_JJ protein_NN (_( MBP_NP ;_: Sigma_NP )_) ,_, ATF2_NP fusion_NN protein_NN (_( 34_CD kDa_NNS ;_: Cell_NP Signaling_NP )_) ,_, or_CC purified_VBD GST-c-Jun_NP as_IN a_DT substrate_NN ._SENT Kinase_NN reactions_NNS were_VBD stopped_VBN after_IN 30_CD min_NN at_IN 25C_JJ with_IN electrophoresis_NN sample_NN buffer_NN ,_, and_CC the_DT reaction_NN mixtures_NNS were_VBD heated_VBN for_IN 5_CD min_NN at_IN 100C_NP ,_, separated_VBN by_IN SDS-PAGE_NP ,_, blotted_VBN onto_IN Hybond-C_NP membranes_NNS (_( Amersham_NP Pharmacia_NP )_) ,_, and_CC analyzed_VBD by_IN autoradiography_NN ._SENT For_IN the_DT Src_NP kinase_NN assay_NN ,_, HEK_NP 293-T_JJ cells_NNS were_VBD transfected_VBN with_IN either_DT 1_CD mug_NN of_IN expression_NN plasmids_NNS for_IN myc-tagged_JJ Src_NP kinase_NN Src_NP ,_, Hck_NP ,_, Lck_NP ,_, Yes_NP ,_, or_CC Fyn_NP or_CC the_DT empty_JJ expression_NN vector_NN ._SENT After_IN transfection_NN ,_, cells_NNS were_VBD kept_VBN in_IN complete_JJ medium_NN with_IN 10_CD %_NN FCS_NN and_CC cells_NNS were_VBD lysed_VBN 24_CD h_NN posttransfection_NN in_IN TBS-T_NP as_RB mentioned_VBD above_IN ._SENT Immunoprecipitation_NN of_IN the_DT myc-tagged_JJ Src_NP kinase_NN was_VBD carried_VBN out_RP overnight_RB with_IN anti-c-myc_JJ antibody-coated_JJ beads_NNS (_( Clontech_NP )_) ._SENT The_DT in_IN vitro_NP kinase_NN reaction_NN was_VBD done_VBN as_IN described_VBN above_IN but_CC with_IN 200_CD ng_NNS of_IN purified_VBN GST-K15355-489_NP or_CC GST-K15355-472_NP fusion_NN protein_NN as_IN the_DT substrate_NN ._SENT For_IN detection_NN of_IN proteins_NNS by_IN Western_JJ blotting_VBG ,_, cleared_VBD cell_NN lysates_NNS or_CC fractions_NNS of_IN the_DT sucrose_NN gradient_NN containing_VBG K15_NP proteins_NNS were_VBD not_RB boiled_VBN prior_RB to_TO SDS-PAGE_NP ._SENT As_IN indicated_VBN ,_, the_DT following_VBG primary_JJ antibodies_NNS were_VBD used_VBN for_IN immunostaining_NN of_IN immunoblots_NNS :_: rabbit_NN anti-JNK1_JJ C-17_NN ,_, mouse_NN anti-Erk2_NP D-2_NP ,_, rabbit_NN anti-p38_NN MAPK_NP H-147_NP ,_, anti-caveolin_NP 1_CD (_( all_DT Santa_NP Cruz_NP Biotech_NP )_) ,_, mouse_NN anti-c-myc_NN 9E10_NN (_( BIOMOL_NP )_) ,_, mouse_NN antiphosphotyrosine_NN P-Thyr-100_NP (_( Cell_NP Signaling_NP )_) ,_, and_CC mouse_NN anti-Flag_NN M2_NP (_( Sigma_NP )_) ._SENT Immunoblots_NNS were_VBD analyzed_VBN with_IN horseradish_NN peroxidase-coupled_JJ secondary_JJ antibodies_NNS (_( DAKO_NP )_) and_CC a_DT standard_JJ enhanced-chemiluminescence_NN reaction_NN (_( Perkin-Elmer_NP )_) ._SENT Coimmunoprecipitation_NP ._SENT |_SYM One_CD day_NN prior_JJ to_TO transfection_NN ,_, 3_CD x_SYM 105_CD HEK_NP 293_CD cells_NNS were_VBD plated_VBN into_IN each_DT well_NN of_IN a_DT six-well_NN plate_NN ._SENT The_DT cells_NNS were_VBD transiently_RB transfected_VBN with_IN 500_CD ng_NNS of_IN either_DT plasmid_NP LMP1-K15355-489_NP or_CC the_DT deletion_NN mutant_JJ form_NN LMP1-K15355-472_NP and_CC 1_CD mug_NN of_IN the_DT cDNA_NN expression_NN construct_NN for_IN Flag-tagged_NP TRAF-1_NP ,_, -2_CD ,_, or_CC -3_CD with_IN the_DT FuGENE_NP transfection_NN reagent_NN ._SENT At_IN 48_CD h_NN posttransfection_NN ,_, cells_NNS were_VBD washed_VBN once_RB in_IN PBS_NP and_CC lysed_VBN in_IN 1_CD %_NN NP-40_JJ lysis_NN buffer_NN containing_VBG protease_NN inhibitors_NNS (_( see_VB above_IN )_) ._SENT Lysates_NNS were_VBD cleared_VBN by_IN centrifugation_NN ,_, and_CC supernatants_NNS were_VBD precleared_VBN with_IN 50_CD mul_NN of_IN protein_NN G_NP Sepharose_NP (_( Amersham_NP Pharmacia_NP )_) ._SENT To_TO 100_CD mul_NN of_IN precleared_JJ lysate_NNS ,_, 0.5_CD mul_NN of_IN rabbit_NN anti-K15_NN serum_NN was_VBD added_VBN ._SENT After_IN 1_CD h_NN of_IN incubation_NN on_IN ice_NN ,_, the_DT protein-antibody_NN complexes_NNS were_VBD incubated_VBN with_IN 20_CD mul_NN of_IN protein_NN G_NP Sepharose_NP beads_NNS at_IN 4C_JJ with_IN gentle_JJ shaking_VBG for_IN 2_CD h._JJ Beads_NNS were_VBD washed_VBN three_CD times_NNS with_IN 1_CD %_NN NP-40_JJ lysis_NN buffer_NN ,_, and_CC bound_JJ proteins_NNS were_VBD recovered_VBN by_IN boiling_VBG in_IN SDS-PAGE_NP sample_NN buffer_NN ._SENT Eluted_VBN proteins_NNS were_VBD analyzed_VBN by_IN Western_NP blotting_VBG as_IN described_VBN above_IN ._SENT Luciferase-based_JJ reporter_NN assays_NNS ._SENT |_SYM To_TO assay_VB NF-kappaB_NP activity_NN ,_, HEK_NP 293-T_JJ cells_NNS were_VBD transiently_RB cotransfected_JJ with_IN 50_CD ng_NNS of_IN the_DT NF-kappaB_NP luciferase_NN reporter_NN plasmid_NN p3EnhkappaBconA-Luc_NN containing_VBG three_CD tandem_JJ repeats_NNS of_IN the_DT NF-kappaB_NP sites_NNS from_IN the_DT immunoglobulin_NN Gkappa_NP promoter_NN and_CC the_DT indicated_JJ amounts_NNS of_IN K15_NP expression_NN constructs_NNS or_CC LMP1_JJ ,_, as_RB mentioned_VBN in_IN the_DT figure_NN legends_NNS ,_, per_IN well_RB of_IN a_DT six-well_NN plate_NN ._SENT At_IN 24_CD h_NN posttransfection_NN ,_, cells_NNS were_VBD washed_VBN with_IN PBS_NP and_CC lysed_VBN in_IN reporter_NN lysis_NN buffer_NN (_( Promega_NP )_) ._SENT Luciferase_NN activities_NNS were_VBD measured_VBN in_IN cleared_VBN lysates_NNS with_IN a_DT luciferase_NN assay_NN system_NN in_IN accordance_NN with_IN the_DT manufacturer_NN 's_POS (_( Promega_NP )_) instructions_NNS ._SENT NF-kappaB_NP activity_NN was_VBD calculated_VBN as_IN fold_NN induction_NN compared_VBN to_TO that_DT of_IN mock_JJ (_( empty_JJ expression_NN vector)-transfected_JJ controls_NNS ._SENT For_IN analysis_NN of_IN AP-1_JJ activity_NN ,_, 50_CD ng_NNS of_IN the_DT reporter_NN plasmid_NN pRTU14_NN or_CC the_DT negative_JJ control_NN reporter_NN pRTU1_NN was_VBD cotransfected_VBN with_IN different_JJ amounts_NNS of_IN K15_NP or_CC LMP1_NP expression_NN constructs_NNS as_RB indicated_VBD in_IN the_DT figure_NN legends_NNS ._SENT Dominant_JJ negative_JJ mutant_JJ forms_NNS of_IN TRAF-2_NP ,_, TRAF-6_NP ,_, Ras_NP ,_, Raf_NP ,_, and_CC Erk2_NP or_CC the_DT respective_JJ empty_JJ expression_NN vectors_NNS were_VBD cotransfected_VBN as_IN indicated_VBN in_IN the_DT figures_NNS ._SENT After_IN transfection_NN ,_, cells_NNS were_VBD maintained_VBN in_IN medium_NN containing_VBG 1_CD %_NN FCS_NN to_TO downregulate_VB serum-activated_JJ signaling_VBG pathways_NNS ._SENT Cells_NNS were_VBD lysed_VBN 24_CD h_NN posttransfection_NN in_IN reporter_NN lysis_NN buffer_NN ,_, and_CC luciferase_NN activity_NN was_VBD assayed_VBN as_IN mentioned_VBN above_IN ._SENT Flotation_NN gradients_NNS ._SENT |_SYM One_CD day_NN prior_JJ to_TO transfection_NN ,_, Cos7_JJ cells_NNS were_VBD plated_VBN in_IN 75-cm2_JJ tissue_NN culture_NN flasks_NNS (_( Costar_NP )_) and_CC transfected_VBD the_DT following_VBG day_NN at_IN similar50_JJ %_NN confluency_NN with_IN Effectene_NP (_( 3.1_CD mug_NN of_IN DNA_NN per_IN 75-cm2_JJ flask_NN )_) in_IN accordance_NN with_IN the_DT manufacturer_NN 's_POS (_( Qiagen_NP )_) instructions_NNS ._SENT At_IN 48_CD h_NN posttransfection_NN ,_, cells_NNS were_VBD washed_VBN once_RB with_IN PBS_NP ,_, trypsinized_JJ ,_, resuspended_JJ in_IN PBS_NP ,_, centrifuged_VBN ,_, washed_VBN with_IN 10_CD ml_NN of_IN PBS_NP ,_, counted_VBN ,_, and_CC pelleted_VBN ._SENT The_DT cell_NN pellets_NNS were_VBD resuspended_VBN in_IN the_DT respective_JJ volumes_NNS of_IN ice-cold_JJ TNE_NP buffer_NN (_( 10_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.4_CD ]_SYM ,_, 150_CD mM_NP NaCl_NP ,_, 5_CD mM_NP EDTA_NP plus_CC protease_NN inhibitors_NNS )_) containing_VBG 1_CD %_NN Triton_NP X-100_NP to_TO adjust_VB the_DT cell_NN concentration_NN to_TO 107_CD cells/ml_NN for_IN all_DT samples_NNS ._SENT Cells_NNS were_VBD lysed_VBN for_IN 30_CD min_NN on_IN ice_NN ,_, homogenized_VBN with_IN a_DT 200-mul_JJ pipette_NN (_( 10_CD strokes_NNS )_) ,_, and_CC centrifuged_VBD for_IN 10_CD min_NN at_IN 900_CD x_NN g_NN at_IN 4C_JJ ._SENT One_CD milliliter_NN of_IN the_DT supernatant_JJ was_VBD mixed_VBN with_IN 1_CD ml_NN of_IN 85_CD %_NN sucrose_NN in_IN TNE_NP and_CC pipetted_VBN onto_IN the_DT bottom_NN of_IN an_DT ultracentrifuge_NN tube_NN (_( 14_CD by_IN 95_CD mm_NN ;_: Beckman_NP )_) ._SENT Six_CD milliliters_NNS of_IN a_DT 35_CD %_NN sucrose_NN solution_NN in_IN TNE_NP was_VBD layered_VBN on_IN top_NN ,_, followed_VBN by_IN 3.5_CD ml_NN of_IN a_DT 5_CD %_NN sucrose_NN solution_NN in_IN TNE_NP ._SENT The_DT samples_NNS were_VBD subjected_VBN to_TO ultracentrifugation_NN at_IN 200,000_CD x_NN g_NN in_IN an_DT SW40_NP rotor_NN for_IN 22_CD h_NN at_IN 4C_JJ ,_, and_CC 1-ml_JJ fractions_NNS were_VBD collected_VBN starting_VBG at_IN the_DT top_NN of_IN the_DT gradient_NN ._SENT The_DT pellet_NN was_VBD resuspended_VBN in_IN 200_CD mul_NN of_IN TNE_NP containing_VBG 1_CD %_NN Triton_NP X-100_NP ._SENT Equal_JJ amounts_NNS of_IN fractions_NNS 1_CD to_TO 12_CD (_( 20_CD mul_NN )_) were_VBD analyzed_VBN by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG (_( of_IN the_DT pellet_NN fraction_NN ,_, only_RB 4_CD mul_NN was_VBD loaded_VBN )_) ._SENT Fractions_NNS 4_CD and_CC 5_CD contain_VBP lipid_NN rafts_NNS and_CC the_DT proteins_NNS associated_VBN with_IN them_PP ._SENT Fractions_NNS 9_CD to_TO 12_CD contain_VBP soluble_JJ and_CC solubilized_VBN proteins_NNS of_IN the_DT nonraft_NN membrane_NN ._SENT Proteins_NNS encoded_VBN by_IN the_DT K15_NP gene_NN and_CC localization_NN in_IN lipid_NN rafts_NNS ._SENT |_SYM The_DT KSHV_NP K15_NP gene_NN encodes_VBZ several_JJ membrane_NN proteins_NNS with_IN a_DT varying_VBG number_NN of_IN transmembrane_NN regions_NNS and_CC a_DT common_JJ cytoplasmic_JJ domain_NN ._SENT The_DT longest_JJS of_IN the_DT K15-encoded_JJ proteins_NNS ,_, containing_VBG all_DT eight_CD exons_NNS ,_, is_VBZ predicted_VBN to_TO give_VB rise_NN to_TO a_DT membrane_NN protein_NN of_IN 489_CD aa_NN with_IN up_IN to_TO 12_CD transmembrane_NN domains_NNS ._SENT When_WRB the_DT K15_NP gene_NN was_VBD transiently_RB expressed_VBN in_IN Cos7_NP ,_, HEK_NP 293_CD ,_, or_CC HEK_NP 293-T_JJ cells_NNS ,_, a_DT protein_NN of_IN similar45_JJ kDa_NNS was_VBD detected_VBN by_IN immunoblotting_VBG with_IN a_DT polyclonal_JJ antiserum_NN raised_VBN against_IN the_DT cytoplasmic_JJ domain_NN of_IN K15_NP (_( Fig._NN and_CC data_NNS not_RB shown_VBN )_) ._SENT Similar_JJ results_NNS were_VBD obtained_VBN with_IN two_CD independently_RB constructed_VBN expression_NN vectors_NNS for_IN the_DT eight-exon_NP K15_NP cDNA_NN (_( see_VB Materials_NNS and_CC Methods_NNS )_) which_WDT were_VBD used_VBN throughout_IN this_DT study_NN ._SENT In_IN addition_NN ,_, we_PP and_CC others_NNS have_VBP recently_RB described_VBN several_JJ splice_NN variants_NNS of_IN K15_NP ._SENT The_DT K15_NP splice_NN variants_NNS examined_VBN in_IN this_DT study_NN are_VBP shown_VBN in_IN Fig._NN ._SENT Whereas_IN K15_NP ex1/6-8_NP uses_VBZ exons_NNS 1_CD ,_, 6_CD ,_, 7_CD ,_, and_CC 8_CD ,_, the_DT splice_NN variants_NNS K15_NP ex1_NP as/6-8_NP and_CC K15_NP ex1_JJ as/4-8_NN use_VB an_DT alternative_JJ splice_NN (_( as_RB )_) in_IN exon_NN 1_CD together_RB with_IN exons_NNS 6_CD ,_, 7_CD ,_, and_CC 8_CD or_CC exons_NNS 4_CD to_TO 8_CD ,_, respectively_RB ._SENT This_DT implies_VBZ the_DT use_NN of_IN a_DT different_JJ reading_NN frame_NN in_IN exon_NN 1_CD ._SENT These_DT three_CD splice_NN variants_NNS are_VBP predicted_VBN to_TO encode_VB proteins_NNS with_IN two_CD to_TO four_CD transmembrane_NN domains_NNS ._SENT When_WRB transiently_RB expressed_VBN in_IN Cos7_JJ cells_NNS ,_, proteins_NNS of_IN approximately_RB 33_CD to_TO 35_CD kDa_NN (_( K15_NP ex1/6-8_NP )_) ,_, 34_CD and_CC 21_CD kDa_NNS (_( K15_NP ex1_JJ as/4-8_NN )_) ,_, and_CC 26_CD and_CC 21_CD kDa_NNS (_( K15_NP ex1_JJ as/6-8_NN )_) were_VBD detected_VBN by_IN immunoblotting_NN with_IN K15_NP polyclonal_JJ antiserum_NN (_( Fig._NN ,_, C_NP ,_, and_CC D_NP )_) ._SENT The_DT 33-_CD to_TO 35-kDa_JJ protein_NN seen_VBN with_IN K15_NP ex1/6-8_NP corresponds_VBZ to_TO the_DT size_NN expected_VBN for_IN this_DT cDNA_NN ,_, as_RB do_VBP the_DT 34-_CD and_CC 26-kDa_JJ proteins_NNS seen_VBN with_IN K15_NP ex1_JJ as/4-8_NN and_CC K15_NP ex1_JJ as/6-8_NN ,_, respectively_RB (_( Fig._NN and_CC D_NN )_) ._SENT The_DT additional_JJ 21-kDa_JJ protein_NN seen_VBN with_IN K15_NP ex1_JJ as/4-8_NN and_CC K15_NP ex1_JJ as/6-8_NN (_( Fig._NN and_CC D_NN )_) may_MD be_VB the_DT result_NN of_IN alternative_NN splicing_VBG ,_, proteolytic_JJ processing_NN ,_, or_CC internal_JJ initiation_NN of_IN translation_NN ._SENT As_IN predicted_VBN ,_, the_DT different_JJ K15_NP protein_NN isoforms_NNS examined_VBN appeared_VBD to_TO be_VB membrane_NN proteins_NNS ,_, since_IN subcellular_JJ fractionation_NN experiments_NNS (_( data_NNS not_RB shown_VBN )_) indicated_VBD that_IN all_DT K15_NP protein_NN isoforms_NNS can_MD be_VB pelleted_VBN with_IN cellular_JJ membranes_NNS after_IN high-speed_JJ centrifugation_NN (_( 100,000_CD x_SYM g_NN )_) of_IN cellular_JJ extracts_VBZ from_IN which_WDT other_JJ organelles_NNS (_( e.g._FW ,_, nuclei_NNS ,_, mitochondria_NNS )_) have_VBP been_VBN depleted_VBN by_IN centrifugation_NN at_IN 1,000_CD x_SYM g._FW In_IN addition_NN ,_, all_DT K15_NP isoforms_NNS are_VBP located_VBN in_IN lipid_NN rafts_NNS ,_, as_RB shown_VBN by_IN flotation_NN experiments_NNS ._SENT Lipid_NN rafts_NNS are_VBP membrane_NN microdomains_NNS rich_JJ in_IN cholesterol_NN and_CC sphingolipids_NNS that_WDT are_VBP resistant_JJ to_TO solubilization_NN with_IN certain_JJ nonionic_JJ detergents_NNS like_IN Triton_NP X-100_NP at_IN 4C_NP ._SENT Hence_RB ,_, lipid_NN rafts_NNS and_CC proteins_NNS associated_VBN with_IN them_PP float_VBP up_RP to_TO a_DT position_NN of_IN lower_JJR density_NN (_( 5_CD to_TO 35_CD %_NN )_) in_IN a_DT sucrose_NN gradient_NN in_IN the_DT presence_NN of_IN 1_CD %_NN Triton_NP X-100_NP ,_, whereas_IN soluble_JJ proteins_NNS and_CC solubilized_VBN membrane_NN proteins_NNS remain_VBP at_IN the_DT bottom_NN of_IN the_DT gradient_NN at_IN the_DT higher_JJR sucrose_NN concentration_NN (_( 35_CD to_TO 42.5_CD %_NN )_) ._SENT As_IN shown_VBN in_IN Fig._NN (_( top_JJ )_) ,_, the_DT 45-kDa_JJ protein_NN derived_VBN from_IN the_DT eight-exon_NP K15_NP cDNA_NN expression_NN construct_VB (_( K15_NP ex1-8_NN ;_: aa_NN 1_CD to_TO 489_CD )_) could_MD be_VB detected_VBN in_IN fractions_NNS 4_CD and_CC 5_CD of_IN the_DT sucrose_NN gradient_NN ,_, which_WDT represent_VBP the_DT interface_NN of_IN 5_CD and_CC 35_CD %_NN sucrose_NN ._SENT These_DT fractions_NNS correspond_VBP to_TO the_DT position_NN of_IN lipid_NN rafts_NNS ,_, as_RB indicated_VBN by_IN the_DT presence_NN of_IN caveolin_NP 1_CD (_( Fig._NN ,_, bottom_JJ )_) ._SENT Caveolin_NP 1_CD is_VBZ a_DT component_NN of_IN caveolae_NNS ,_, which_WDT represent_VBP a_DT specialized_JJ subset_NN of_IN lipid_NN rafts_NNS ._SENT K15_NN proteins_NNS of_IN 33_CD to_TO 35_CD kDa_NN (_( splice_VB variant_JJ K15_NP ex1/6-8_NN in_IN Fig._NN )_) and_CC 21_CD kDa_NN (_( splice_NN variants_NNS K15_NP ex1_JJ as/4-8_NN in_IN Fig._NN and_CC K15_NP ex1_JJ as/6-8_NN in_IN Fig._NN )_) also_RB floated_VBD to_TO the_DT same_JJ position_NN in_IN the_DT sucrose_NN gradient_NN ._SENT Only_RB a_DT portion_NN of_IN the_DT K15_NP proteins_NNS was_VBD incorporated_VBN into_IN lipid_NN rafts_NNS ._SENT On_IN the_DT basis_NN of_IN densitometry_NN scanning_VBG of_IN the_DT blots_NNS shown_VBN in_IN Fig._NN ,_, we_PP estimate_VBP that_IN 21_CD %_NN of_IN the_DT 45-kDa_JJ immunoreactive_JJ K15_NP protein_NN (_( K15_NP ex1-8_NP )_) (_( excluding_VBG the_DT material_NN in_IN the_DT pellet_NN fraction_NN )_) was_VBD present_JJ in_IN lipid_NN rafts_NNS ._SENT For_IN the_DT smaller_JJR 33-_CD to_TO 35-kDa_NP K15_NP ex1/6-8_JJ splice_NN variant_NN ,_, a_DT comparable_JJ amount_NN (_( 26_CD %_NN )_) was_VBD found_VBN in_IN lipid_NN rafts_NNS ,_, in_IN contrast_NN to_TO only_RB 5_CD %_NN in_IN the_DT case_NN of_IN K15_NP ex1_JJ as/4-8_NN and_CC a_DT similar_JJ small_JJ proportion_NN in_IN the_DT case_NN of_IN K15_NP ex1_JJ as/6-8_NN ._SENT It_PP thus_RB appears_VBZ that_IN the_DT K15_NP ex1_JJ as/4-8_NN and_CC K15_NP ex1_JJ as/6-8_NN proteins_NNS were_VBD incorporated_VBN less_RBR efficiently_RB than_IN the_DT 45-kDa_NP (_( K15_NP ex1-8_NP )_) and_CC 33-_CD to_TO 35-kDa_NP (_( K15_NP ex1/6-8_NN )_) isoforms_NNS ._SENT The_DT eight-exon_NP 45-kDa_NP K15_NP protein_NN (_( K15_NP ex1-8_NN ;_: aa_NN 1_CD to_TO 489_CD )_) was_VBD also_RB detected_VBN in_IN fractions_NNS 10_CD ,_, 11_CD ,_, and_CC 12_CD (_( sucrose_NN concentrations_NNS of_IN 35_CD to_TO 42.5_CD %_NN )_) of_IN the_DT sucrose_NN gradient_NN ,_, where_WRB solubilized_VBN membrane_NN proteins_NNS would_MD be_VB expected_VBN (_( Fig._NN ,_, top_JJ )_) ._SENT This_DT result_NN is_VBZ reminiscent_JJ of_IN LMP1_NP and_CC LMP2A_NP ,_, which_WDT are_VBP both_CC localized_VBN to_TO lipid_NN rafts_NNS and_CC also_RB to_TO nonraft_NN cell_NN membranes_NNS ._SENT The_DT 45-kDa_NP K15_NP protein_NN could_MD also_RB be_VB detected_VBN in_IN the_DT pellet_NN fraction_NN containing_VBG cytoskeleton-associated_JJ proteins_NNS (_( Fig._NN ,_, top_JJ )_) ,_, which_WDT was_VBD also_RB observed_VBN for_IN the_DT LMP1_JJ protein_NN but_CC not_RB for_IN LMP2A_NP by_IN Higuchi_NP et_FW al._FW ._SENT A_DT chimeric_JJ LMP1/K15_NP protein_NN ,_, containing_VBG the_DT six_CD LMP1_JJ transmembrane_NN domains_NNS fused_VBD to_TO the_DT cytoplasmic_JJ region_NN of_IN K15_NP ,_, was_VBD also_RB found_VBN in_IN lipid_NN rafts_NNS and_CC nonraft_NN cell_NN membranes_NNS ._SENT K15_JJ protein_NN binds_NNS to_TO and_CC is_VBZ phosphorylated_JJ by_IN members_NNS of_IN the_DT Src_NP kinase_NN family_NN ._SENT |_SYM Since_IN K15_NP resembles_VBZ the_DT LMP2A_NP protein_NN of_IN EBV_NP with_IN respect_NN to_TO its_PP$ genomic_JJ localization_NN at_IN the_DT right_JJ end_NN of_IN the_DT genome_NN ,_, its_PP$ protein_NN structure_NN with_IN 12_CD putative_JJ transmembrane_NN domains_NNS ,_, the_DT presence_NN of_IN putative_JJ binding_JJ sites_NNS for_IN SH2_NP and_CC SH3_NP motifs_NNS in_IN the_DT cytoplasmic_JJ domain_NN ,_, and_CC its_PP$ localization_NN in_IN lipid_NN rafts_NNS ,_, we_PP examined_VBD whether_IN K15_NP has_VBZ functional_JJ characteristics_NNS in_IN common_JJ with_IN LMP2A_NP ._SENT It_PP has_VBZ previously_RB been_VBN shown_VBN that_IN K15_NP is_VBZ constitutively_RB phosphorylated_JJ on_IN the_DT tyrosine_NN within_IN the_DT distal_JJ putative_JJ SH2-binding_NP motif_NN Y481EEVL_NP ._SENT Since_IN LMP2A_NP is_VBZ phosphorylated_JJ at_IN its_PP$ ITAM_NN by_IN members_NNS of_IN the_DT nonreceptor_NN protein_NN tyrosine_NN kinase_NN (_( PTK_NP )_) family_NN ,_, we_PP investigated_VBD whether_IN K15_NP is_VBZ a_DT substrate_NN for_IN these_DT kinases_NNS ._SENT The_DT complete_JJ cytoplasmic_JJ C-terminal_JJ domain_NN of_IN K15_NP fused_VBD to_TO GST_NP (_( GST-K15355-489_NP )_) and_CC the_DT deletion_NN mutant_JJ form_NN GST-K15355-472_NP lacking_VBG the_DT distal_JJ SH2-binding_NP motif_NN (_( Y481EEVL_NP )_) were_VBD expressed_VBN in_IN E._NP coli_NNS and_CC purified_VBD as_RB described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT The_DT purified_VBN fusion_NN proteins_NNS were_VBD analyzed_VBN by_IN SDS-PAGE_NP (_( data_NN not_RB shown_VBN )_) ,_, and_CC equal_JJ amounts_NNS of_IN protein_NN were_VBD used_VBN as_IN the_DT substrate_NN in_IN an_DT in_IN vitro_NP kinase_NN assay_NN with_IN immunoprecipitated_JJ myc-tagged_JJ PTKs_NP Src_NP ,_, Fyn_NP ,_, Lck_NP ,_, Hck_NP ,_, and_CC Yes_NP from_IN transiently_RB transfected_JJ HEK_NP 293-T_JJ cells_NNS ._SENT Figure_NN shows_VBZ that_IN all_DT of_IN the_DT kinases_NNS examined_VBD phosphorylated_JJ the_DT C-terminal_JJ domain_NN of_IN K15_NP (_( GST-_NP 